Firsocostat Explained

Firsocostat is an acetyl-CoA carboxylase inhibitor that functions in the liver. Its original designation was GS-0976.[1] It was discovered by Nimbus Therapeutics.[2] The drug is under development by Gilead as a treatment for non-alcoholic fatty liver disease.[3]

Notes and References

  1. Alkhouri . Naim . Lawitz . Eric . Noureddin . Mazen . DeFronzo . Ralph . Shulman . Gerald I. . GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) . Expert Opinion on Investigational Drugs . 1 February 2020 . 29 . 2 . 135–141 . 10.1080/13543784.2020.1668374. 31519114 . 7063378 .
  2. Harriman . Geraldine . Greenwood . Jeremy . Bhat . Sathesh . Huang . Xinyi . Wang . Ruiying . Paul . Debamita . Tong . Liang . Saha . Asish K. . Westlin . William F. . Kapeller . Rosana . Harwood . H. James . Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats . Proceedings of the National Academy of Sciences . 29 March 2016 . 113 . 13 . E1796-805 . 10.1073/pnas.1520686113 . 26976583 . 4822632 . 2016PNAS..113E1796H . free .
  3. Alkhouri . Naim . NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges . Expert Opinion on Investigational Drugs . 1 February 2020 . 29 . 2 . 87 . 10.1080/13543784.2020.1721169. 31984804 . 210924006 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Firsocostat".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.